Company Overview - Star Lake Technology, established on April 18, 1992, and listed on August 18, 1994, is located in Zhaoqing, Guangdong Province. The company specializes in the research, production, and sales of food additives, feed additives, chemical raw materials, and pharmaceutical intermediates [1]. Financial Performance - For the first half of 2025, Star Lake Technology reported a revenue of 8.16 billion yuan, a year-on-year decrease of 3.85%. However, the net profit attributable to shareholders increased by 65.22% to 836 million yuan [2]. - The company has cumulatively distributed 1.57 billion yuan in dividends since its A-share listing, with 1.26 billion yuan distributed over the past three years [3]. Stock Performance - As of September 30, Star Lake Technology's stock price increased by 2.01% to 7.61 yuan per share, with a total market capitalization of 12.644 billion yuan. The stock has risen by 24.96% year-to-date [1]. - The stock's trading volume on September 30 was 124 million yuan, with a turnover rate of 1.31% [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 7% to 44,800, while the average circulating shares per person increased by 7.53% to 24,754 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third-largest, holding 36.2164 million shares, an increase of 25.2508 million shares from the previous period [3].

Group 1: Company Overview and Performance - The company, Guangdong Yiduoli Biotechnology Co., Ltd., focuses on two main sectors: animal feed and industrial enzyme products [1][2] - In 2024, the company expects to produce 41,533 tons of biological enzyme preparations, with sales reaching 42,383 tons, resulting in a sales rate exceeding 100% [8] - The sales proportion of the top five customers in 2024 is 13.75%, with domestic and international market shares at 67.59% and 32.41% respectively [8] Group 2: Market Expectations and Product Development - The company anticipates stable growth in both domestic and international markets for its industrial enzyme products, which cover various applications including bioenergy and food [2][7] - New product developments include biodegradable enzymes for environmental applications, with R-PET enzyme currently in the conversion stage [6][7] - The company has developed a high-yield strain of calcium propionate to replace traditional chemical synthesis methods, with ongoing optimization of previously developed products [3] Group 3: Risk Management and Financial Health - The company maintains a focus on asset quality, with no current pressure for asset impairment due to proactive management and dynamic assessments [4][5] - A customer credit evaluation system is in place to manage accounts receivable risks, while dynamic inventory management helps mitigate stock depreciation [4] Group 4: Strategic Initiatives and International Expansion - The company is expanding its international presence, with a completed German subsidiary and a planned Brazilian subsidiary to enhance market opportunities [7][9] - The company is committed to enhancing its marketing network and local brand development in overseas markets [7][9] Group 5: Competitive Landscape and Regulatory Environment - The company is positioned to benefit from the "antibiotic-free" policy in the feed industry, with plant extracts gaining market traction despite higher costs compared to antibiotics [6] - The company faces some pressure from market demand fluctuations in the domestic livestock industry, but expects growth as the industry recovers [6]

证券日报网讯美农生物9月25日在互动平台回答投资者提问时表示，公司当前聚焦饲料添加剂和酶解蛋 白饲料原料的研发、生产和销售，暂不涉及疫苗的研发、生产和销售。公司将结合产业政策、行业发展 趋势、市场与客户需求等，持续迭代升级现有产品，研究开发高效、安全、环保型的饲料添加剂和酶解 蛋白饲料原料产品及其应用方案。 （文章来源：证券日报） ...

美农生物（301156.SZ）9月25日在投资者互动平台表示，尊敬的投资者，您好！公司当前聚焦饲料添加 剂和酶解蛋白饲料原料的研发、生产和销售，暂不涉及疫苗的研发、生产和销售。公司将结合产业政 策、行业发展趋势、市场与客户需求等，持续迭代升级现有产品，研究开发高效、安全、环保型的饲料 添加剂和酶解蛋白饲料原料产品及其应用方案。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司有没有考虑过开发动物添加剂疫苗，酶解 蛋白疫苗，动物直接注入，不用掺到饲料里，效果一样？ ...

格隆汇9月25日丨美农生物(301156.SZ)在互动平台表示，公司当前聚焦饲料添加剂和酶解蛋白饲料原料 的研发、生产和销售，暂不涉及疫苗的研发、生产和销售。公司将结合产业政策、行业发展趋势、市场 与客户需求等，持续迭代升级现有产品，研究开发高效、安全、环保型的饲料添加剂和酶解蛋白饲料原 料产品及其应用方案。 ...

点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 责任编辑：小浪快报 为提升公司治理效能，永安药业拟对《公司章程》部分条款进行修订。董事会成员人数将由6名增至7 名，增设1名职工代表董事和1名副董事长。同时，取消监事会及监事，原监事会职权转由董事会审计委 员会履行，《监事会议事规则》等监事会相关制度相应废止。本次修订尚需提交公司股东会审议，董事 会提请股东会授权办理后续工商变更、章程备案等事宜。 为完善公司治理制度，促进规范运作，永安药业拟对部分治理制度进行制定及修订。涉及修订的制度包 括《股东会议事规则》《董事会议事规则》《独立董事工作制度》等11项，其中3项尚需提交公司股东 会审议，其余制度自董事会审议通过之日起生效。具体 ...

在产品方面，周茜称，公司除了持续深耕猪、奶牛和家禽市场和布局水产、肉牛羊等市场外，还将继续 加大对研发资源的投入，开发与研究高效、安全、环保型的饲料添加剂和酶解蛋白饲料原料产品及其应 用方案。公司"年产10万吨玉米蛋白精加工项目"预计在今年建成并进行试生产，项目建成投产后将正式 向市场推出玉米浓缩蛋白和玉米酶解蛋白等系列产品，对缓解国内饲料蛋白资源紧缺的现状有积极作 用，对公司业务发展将带来新的增长点。 沟通传递价值 信心共筑未来——2025年上海辖区上市公司集体接待日暨中报业绩说明会9月19日在全景 网举行。美农生物（301156）财务总监周茜表示，公司下半年将坚持"深耕国内 突破国际"的市场战略 和"分种分品、全程营养"的产品战略。在国内市场，公司聚焦核心客户开发，实施"扩一品工程"，双升 服务、交叉销售，既实现客户采购成本最优，又实现了客户价值最大化。在海外市场，坚持"走出去、 请进来"的海外市场发展策略，不断投入资源加大对国际市场的开拓力度。 美农生物专业从事饲料添加剂和酶解蛋白饲料原料研发、生产和销售。 ...

天眼查App显示，近日，射阳新希望生物科技有限公司成立，法定代表人为王敏，注册资本2000万人民 币，经营范围包括饲料生产、饲料添加剂生产、水产养殖等。股权全景穿透图显示，该公司由新希望旗 下山东新希望六和集团有限公司全资持股。 ...

证券日报网讯 美农生物（301156）9月22日发布公告，在公司回答调研者提问时表示，公司始终坚 持"产品领先、价值服务、伙伴成长"的价值主张，紧紧围绕产品、市场、客户、效率等方面开展工作。 在产品端，公司践行"分种分品、全程营养"的产品战略，持续加大产品研发与创新投入，不断推出贴合 市场需求的新产品、新技术。从财务表达看，2025年上半年，公司主营饲料添加剂和酶解蛋白饲料原料 业务收入较上年同期均实现不同程度的增长，其中，饲料添加剂板块的肠道健康类产品表现尤为突出， 其收入同比增长超60%，是公司业绩增长的重要来源。在市场端，公司践行"深耕国内、突破国际"的市 场战略，组建了专业的国内、国际营销团队和价值服务团队，推动公司境内外业务双向发展，就财务结 果而言，公司境内外业务收入在今年上半年较上年同期皆实现不同程度的增长。在境内业务拓展方面， 公司实施变革创新，通过拓宽种类市场、做深客户市场、做强核心产品，推动境内业务逆势成长。在境 外业务拓展方面，公司一手抓"走出去"，持续开发新市场、扩张业务版图；一手抓"扎下去"，对现有市 场进行"价值深耕"，两力并举，提质增量，持续保持20%以上的增长。同时，公司通过不 ...

Group 1: Company Overview and Strategy - Shanghai Meinong Biological Technology Co., Ltd. focuses on "product leadership, value service, and partner growth" as its core value proposition [2] - The company implements a product strategy of "diversified species and products, full-process nutrition" to enhance product development and innovation [2][4] Group 2: Financial Performance - In the first half of 2025, the company reported revenue and profit growth, with feed additive revenue increasing by over 60% year-on-year, significantly contributing to overall performance [3] - Domestic and international business revenues both experienced growth, with international business revenue increasing by over 20% in the first half of 2025 [6] Group 3: Project Development - The company’s wholly-owned subsidiary, Leiling Meinong, is on track to complete its 100,000-ton corn protein deep processing project by the end of 2025 [3][4] - The project aims to alleviate the domestic protein resource shortage by utilizing corn by-products, aligning with national policies for diversified food supply systems [4][5] Group 4: Product Planning and Market Strategy - The project will launch corn concentrated protein and corn enzymatic protein products, enhancing nutritional value and meeting market demands [5] - The company has established a robust market network across over 20 provinces in China and several countries worldwide, supporting the promotion of its new products [5] Group 5: Research and Innovation - The company emphasizes innovation, achieving breakthroughs in feed additives and enzymatic protein feed materials, including a new gut health product and enhanced protein digestibility solutions [8][9] - Collaborative research with academic institutions aims to address industry challenges and expand product applications, creating new business opportunities [10]